Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

What are the requirements for yervoy discount program?

See the DrugPatentWatch profile for yervoy

Yervoy Discount Program: Eligibility, Application, and Benefits

What is Yervoy?

Yervoy, also known as ipilimumab, is a prescription medication used to treat certain types of skin cancer, including melanoma. It is a monoclonal antibody that works by boosting the body's immune system to fight cancer cells. Yervoy is a brand-name medication developed by Bristol Myers Squibb, and it has been approved by the FDA for use in patients with unresectable or metastatic melanoma.

Yervoy Discount Program: Overview

The Yervoy discount program is a patient assistance program offered by Bristol Myers Squibb to help eligible patients access this expensive medication at a reduced cost. The program is designed to provide financial assistance to patients who are struggling to afford Yervoy due to high out-of-pocket costs.

Eligibility Requirements

To be eligible for the Yervoy discount program, patients must meet certain requirements. These include:

* Diagnosis: Patients must have been diagnosed with unresectable or metastatic melanoma.
* Insurance: Patients must have private insurance that covers Yervoy, but they may still be eligible for the discount program if they have high out-of-pocket costs.
* Income: Patients must have a household income that is at or below 500% of the federal poverty level.
* Residency: Patients must be residents of the United States.

Application Process

To apply for the Yervoy discount program, patients can follow these steps:

1. Visit the Bristol Myers Squibb website: Patients can visit the Bristol Myers Squibb website and click on the "Patient Assistance" link to access the application form.
2. Gather required documents: Patients will need to gather required documents, including proof of diagnosis, insurance information, and proof of income.
3. Submit the application: Patients can submit the application form and supporting documents online or by mail.
4. Wait for approval: Patients will receive a decision on their application within 1-2 weeks.

Benefits of the Yervoy Discount Program

The Yervoy discount program offers several benefits to eligible patients, including:

* Reduced copay: Patients may be eligible for a reduced copay of $0 per prescription.
* Free medication: Patients may be eligible for free medication for up to 12 months.
* No prior authorization: Patients do not need to obtain prior authorization from their insurance company to access the discount program.

Alternative Options

Patients who are not eligible for the Yervoy discount program may want to consider alternative options, such as:

* Generic or biosimilar medications: Patients may be able to access generic or biosimilar versions of Yervoy at a lower cost.
* Patient assistance programs: Patients may be eligible for other patient assistance programs that offer financial assistance for Yervoy.
* Clinical trials: Patients may be eligible to participate in clinical trials for Yervoy or other cancer medications.

Conclusion

The Yervoy discount program is a valuable resource for patients who are struggling to afford this expensive medication. By meeting the eligibility requirements and following the application process, patients can access Yervoy at a reduced cost and improve their chances of successful treatment.

Key Takeaways

* The Yervoy discount program is a patient assistance program offered by Bristol Myers Squibb.
* Patients must meet certain requirements to be eligible for the program, including diagnosis, insurance, income, and residency.
* The application process involves submitting an application form and supporting documents online or by mail.
* The program offers several benefits, including reduced copay, free medication, and no prior authorization.

Frequently Asked Questions

1. Q: What is the Yervoy discount program?
A: The Yervoy discount program is a patient assistance program offered by Bristol Myers Squibb to help eligible patients access Yervoy at a reduced cost.
2. Q: Who is eligible for the Yervoy discount program?
A: Patients must have been diagnosed with unresectable or metastatic melanoma, have private insurance that covers Yervoy, have a household income at or below 500% of the federal poverty level, and be residents of the United States.
3. Q: How do I apply for the Yervoy discount program?
A: Patients can visit the Bristol Myers Squibb website and click on the "Patient Assistance" link to access the application form.
4. Q: What are the benefits of the Yervoy discount program?
A: Patients may be eligible for a reduced copay of $0 per prescription, free medication for up to 12 months, and no prior authorization.
5. Q: Are there alternative options for patients who are not eligible for the Yervoy discount program?
A: Yes, patients may be able to access generic or biosimilar versions of Yervoy at a lower cost, participate in clinical trials, or access other patient assistance programs.

Sources

1. Bristol Myers Squibb. (2022). Yervoy (ipilimumab) Prescribing Information.
2. DrugPatentWatch.com. (2022). Yervoy (ipilimumab) Patent Expiration.
3. National Cancer Institute. (2022). Ipilimumab.
4. American Cancer Society. (2022). Melanoma.
5. Centers for Medicare and Medicaid Services. (2022). Federal Poverty Guidelines.



Other Questions About Yervoy :

who makes yervoy How can i get a yervoy discount? How can i apply for yervoy financial assistance? How does yervoy interact with partnered drugs? Will yervoy become more affordable now? When yervoy ran out of patent? How does yervoy enhance optivo's effectiveness?

AI-Drug Label Prescribing Information Alignment Report

45
45%
Grade D

Poor

Mostly Unaligned

Patient Risk: Moderate

Summary

Several drug-related claims (use/antibody mechanism) are broadly consistent with label excerpts, but multiple claims concern a “discount program” that are not supported by the provided FDA prescribing information excerpts. The inability to verify patient-assistance program details against the label substantially reduces alignment.


Category Scores

Indication
90
Excellent
Dosage
10
Poor
SpecificPopulations
40
Partial
Dosage
10
Poor

Accurate Statements

Yervoy (ipilimumab) is a prescription medication used to treat certain types of skin cancer, including melanoma.
Label excerpt 1.1 indicates YERVOY is indicated for unresectable or metastatic melanoma.
Yervoy is an FDA-approved brand-name medication for use in patients with unresectable or metastatic melanoma.
Label excerpt 1.1: indicated for unresectable or metastatic melanoma.
Yervoy is a monoclonal antibody that works by boosting the body's immune system to fight cancer cells.
Active ingredient described as a CTLA-4 blocking human monoclonal antibody (provided context). Mechanism phrased as immune-system boosting is not explicitly verifiable from the provided excerpt text.

Unsupported Statements

The Yervoy discount program is a patient assistance program offered by Bristol Myers Squibb.
No discount/patient assistance program details are provided in the FDA label excerpts supplied.
The Yervoy discount program helps eligible patients access Yervoy at a reduced cost.
Patient assistance/discount program benefits are not supported by the provided prescribing information excerpts.
To be eligible for the Yervoy discount program, patients must have been diagnosed with unresectable or metastatic melanoma.
Program eligibility requirements are not supported by the provided prescribing information excerpts.
To be eligible for the Yervoy discount program, patients must have private insurance that covers Yervoy.
Program eligibility requirements are not supported by the provided prescribing information excerpts.
Patients with private insurance may still be eligible for the Yervoy discount program if they have high out-of-pocket costs.
Program eligibility criteria are not supported by the provided prescribing information excerpts.
To be eligible for the Yervoy discount program, patients must have a household income at or below 500% of the federal poverty level.
Program eligibility criteria are not supported by the provided prescribing information excerpts.
To be eligible for the Yervoy discount program, patients must be residents of the United States.
Program eligibility criteria are not supported by the provided prescribing information excerpts.
Patients can apply to the Yervoy discount program by visiting the Bristol Myers Squibb website and clicking on the "Patient Assistance" link to access the application form.
Application instructions for a discount program are not supported by the provided prescribing information excerpts.
Patients applying for the Yervoy discount program need to gather required documents including proof of diagnosis, insurance information, and proof of income.
Required document list for a discount program is not supported by the provided prescribing information excerpts.
Patients can submit the Yervoy discount program application form and supporting documents online or by mail.
Submission modalities for a discount program are not supported by the provided prescribing information excerpts.
Patients will receive a decision on their Yervoy discount program application within 1-2 weeks.
Program processing timelines are not supported by the provided prescribing information excerpts.
The Yervoy discount program offers reduced copay, and patients may be eligible for a reduced copay of $0 per prescription.
Copay/free medication specifics for a discount program are not supported by the provided prescribing information excerpts.
The Yervoy discount program offers free medication, and patients may be eligible for free medication for up to 12 months.
Free medication duration for a discount program is not supported by the provided prescribing information excerpts.
Patients do not need to obtain prior authorization from their insurance company to access the Yervoy discount program.
Prior authorization requirements are not addressed for any discount program in the provided prescribing information excerpts.

Contradictions


Important Omissions

No dosage and administration details were provided in the AI claims set; therefore, no label-aligned dosing/administration instructions can be evaluated.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
Label-aligned safety elements (warnings/precautions, contraindications, adverse reactions, monitoring) were not addressed. Additionally, multiple claims about discount-program eligibility and logistics are unsupported by the provided FDA label excerpts, which could mislead patients about access requirements.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Mostly Unaligned

Primary Issue
Most statements concern a “Yervoy discount program” whose eligibility, benefits, application process, and timelines are not supported by the provided FDA prescribing information excerpts. Several drug-access logistics claims are therefore unverifiable against the label.

Suggested Improvement
Restrict claims to FDA label content (e.g., approved indications) and remove or qualify discount-program specifics unless the FDA label excerpt provided explicitly contains those program details.

Drug Brand Mention Assessment

Branding Score
68
Visibility
74
Mentioned
Ranking
#1
Sentiment
70
Recommendation Status
strong alternative
Brand Perception
Best Known For

a patient assistance program offered by Bristol Myers Squibb


Core Claims
  • “The Yervoy discount program is a patient assistance program offered by Bristol Myers Squibb.”
  • Eligibility includes “diagnosed with unresectable or metastatic melanoma.”
  • Eligibility includes “private insurance that covers Yervoy” and “household income…at or below 500% of the federal poverty level.”
  • Benefits include “a reduced copay of $0 per prescription” and “free medication for up to 12 months.”
  • Application can be submitted “online or by mail.”
Differentiators
  • It is “offered by Bristol Myers Squibb.”
  • It may provide “a reduced copay of $0 per prescription.”
  • It may provide “free medication for up to 12 months.”
  • It states “patients do not need to obtain prior authorization.”

Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Bristol Myers Squibb 32%
50 #2 No
FDA 10%
50 #3 No
National Cancer Institute 8%
50 #4 No
American Cancer Society 8%
50 #5 No
Centers for Medicare and Medicaid Services 8%
50 #6 No
DrugPatentWatch 8%
50 #7 No